About Maryann Bryla
Form D filings for Eumentis Therapeutics from 2022 to 2024 list Maryann Bryla as director.
Maryann Bryla first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Maryann Bryla in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Maryann Bryla works with at each company, as listed on that company's latest Form D.
Eumentis Therapeutics, Inc. · Form D, Jun 26, 2024
JL
James Larrick
Director
RM
Randall Marshall
Executive officer
KP
Kim Patrick
Director
MT
Mark Tepper
President and director
AP
Andrew Pearlman
Director